A phase 2 study of weekly albumin-bound paclitaxel (Abraxane ®) given as a two-hour infusion

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1331-1337

  Paik, Paul K ^a   James, Leonard P ^a   Riely, Gregory J ^a   Azzoli, Christopher G ^a   Miller, Vincent A ^a   Ng, Kenneth K ^a   Sima, Camelia S ^a   Heelan, Robert T ^a   Kris, Mark G ^a   Moore, Erin ^a   Rizvi, Naiyer A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Abraxane; Albumin bound paclitaxel; Neuropathy; Non small cell lung cancer

Indexed keywords

PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; INCIDENCE; INFUSION RATE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 82455175226     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1621-0     Document Type: Article

References (20)

1. Blum JL, Savin MA, Edelman G, Pippen JE, Robert N, Sandbach J, Carrasco S, O'Shaughnessy JA (2004) Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol (Meeting Abstracts) 22(14S):abstr 543
2. E Eisenhauer W ten Bokkel Huinink K Swenerton L Gianni J Myles M van der Burg I Kerr J Vermorken K Buser N Colombo 1994 European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion J Clin Oncol 12 2654 2666 7989941 1:STN:280:DyaK2M%2FotFyjtQ%3D%3D (Pubitemid 24379653)
3. R Freilich C Balmaceda A Seidman 1996 Motor neuropathy due to docetaxel and paclitaxel Neurology 47 115 118 8710063 1:CAS:528:DyaK28XkvFalt7o%3D (Pubitemid 26243870)
4. WJ Gradishar S Tjulandin N Davidson H Shaw N Desai P Bhar M Hawkins J O'Shaughnessy 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 7794 7803 16172456 10.1200/JCO.2005.04.937 1:CAS:528:DC%2BD2MXht1Cqs7nK (Pubitemid 46657376)
5. ®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann Oncol 17 1263 1268 16740598 10.1093/annonc/mdl104 1:STN:280:DC%2BD28vkvVOrsw%3D%3D (Pubitemid 44288216)
6. Ibrahim N, Samuels B, Page R, Guthrie G, Hortobagyi G (2002) Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): Efficacy and evidence of dose-dependent activity in two multicenter phase II studies.In: Proceedings of American Society Clinical Oncology 21:abstr 209
7. NK Ibrahim B Samuels R Page D Doval KM Patel SC Rao MK Nair P Bhar N Desai GN Hortobagyi 2005 Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J Clin Oncol 23 6019 6026 16135470 10.1200/JCO.2005.11.013 1:CAS:528:DC%2BD2MXhtVKgtb3I
8. JJ Lee SM Swain 2006 Peripheral neuropathy induced by microtubule-stabilizing agents J Clin Oncol 24 1633 1642 16575015 10.1200/JCO.2005.04.0543 1:CAS:528:DC%2BD28XjvFyktLs%3D (Pubitemid 46638788)
9. S Mielke A Sparreboom SM Steinberg H Gelderblom C Unger D Behringer K Mross 2005 Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer Clin Cancer Res 11 4843 4850 16000582 10.1158/1078-0432.CCR-05-0298 1:CAS:528:DC%2BD2MXlvVGgs7w%3D (Pubitemid 41557204)
10. O'Shaughnessy J BJ, Sandbach J (2004) Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. In: Proceedings of 27th annual San Antonio breast cancer symposium, San Antonio, TX. abstr 1070
11. T Peretz A Sulkes P Chollet K Gelmon R Paridaens V Gorbonuva G Catimel H Kuhnle Huinink WtB D Khayat C Ditrich U Klaassen J Bergh N Wilking JM Nabholtz F Calabresi M Tubiana-Hulin M Chazard G Gallant K Diergarten R Westberg J Bogaert J Renard C Weil 1995 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC) Eur J Cancer 31 75 75 10.1016/0959-8049(95)95598-Z
12. M Ranson N Davidson M Nicolson S Falk J Carmichael P Lopez H Anderson N Gustafson A Jeynes G Gallant T Washington N Thatcher 2000 Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer J Natl Cancer Inst 92 1074 1080 10880550 10.1093/jnci/92.13.1074 1:CAS:528:DC%2BD3cXlsVChurc%3D (Pubitemid 30616481)
13. NA Rizvi GJ Riely CG Azzoli VA Miller KK Ng J Fiore G Chia M Brower R Heelan MJ Hawkins MG Kris 2008 Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer J Clin Oncol 26 639 643 18235124 10.1200/JCO.2007.10. 8605 1:CAS:528:DC%2BD1cXis1alsb4%3D (Pubitemid 351264360)
14. K Roszkowski A Pluzanska M Krzakowski AP Smith E Saigi U Aasebo A Parisi N Pham Tran R Olivares J Berille 2000 A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small-cell lung cancer (NSCLC) Lung Cancer 27 145 157 10699688 10.1016/S0169-5002(00)00094-5 1:STN:280:DC%2BD3c7msFWmtQ%3D%3D (Pubitemid 30105654)
15. M Roytta S Raine 1986 Taxol induced neuropathy: chronic effects of local injection J Neurocytol 15 483 496 2427662 10.1007/BF01611731 1:CAS:528:DyaL28Xls1Cmurg%3D (Pubitemid 16045885)
16. AD Seidman D Berry C Cirrincione L Harris H Muss PK Marcom G Gipson H Burstein D Lake CL Shapiro P Ungaro L Norton E Winer C Hudis 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all her-2 overexpressors and random assignment to trastuzumab or not in her-2 non-overexpressors: final results of cancer and leukemia group b protocol 9840 J Clin Oncol 26 1642 1649 18375893 10.1200/JCO.2007.11.6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D
17. RE Smith AM Brown EP Mamounas SJ Anderson BC Lembersky JH Atkins HR Shibata L Baez PA DeFusco E Davila SJ Tipping JD Bearden MP Thirlwell 1999 Randomized trial of 3 h versus 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: national surgical adjuvant breast and bowel project protocol b-26 J Clin Oncol 17 3403 3411 10550134 1:CAS:528:DyaK1MXnvVGlt78%3D (Pubitemid 29517907)
18. Socinski M, Bondarenko I, Karaseva N, Makhson A, Vynnychenko I, Okamoto I, Hon J (2010) Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with Cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 28:abstr 7511
19. MA Socinski GM Manikhas DL Stroyakovsky AN Makhson SV Cheporov SV Orlov PK Yablonsky PH Bhar J Iglesias 2010 A dose finding study of weekly and every 3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer J Thorac Oncol 5 852 861 20521351 10.1097/JTO.0b013e3181d5e39e
20. Stokes M, Davis C, Koch G (2000) Categorical data analysis using the sas system, 2nd edn. SAS Institute and Wiley, Cary